Dividends & Buybacks ·
Novo Nordisk provided an update on its share repurchase programme, which aims to repurchase up to DKK 15 billion in…
NVONovo Nordisk A S
Novo Nordisk provided an update on its share repurchase programme, which aims to repurchase up to DKK 15 billion in shares during a 12-month period starting 4 February 2026. Since 29 June 2026, the company repurchased 1,000,000 B shares at prices ranging from DKK 314.24 to DKK 326.71, totaling DKK 65,342,713. As of 3 July 2026, the total number of B shares repurchased under the programme since 4 February 2026 is 23,009,179, with an average price of DKK 270.32 and a total transaction value of DKK 6,219,775,971. The company currently holds 40,194,480 B shares as treasury shares. Novo Nordisk is a global healthcare company specializing in diabetes and chronic disease treatments.